Santhera Enters into License Agreement with Chiesi Group for Raxone in LHON Valued at up to CHF 105…
Santhera Pharmaceuticals announces that it has entered into an exclusive license agreement with Chiesi Farmaceutici, an international research-focused healthcare group (Chiesi Group),…
Read More...
Read More...
